Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene to Present at the Jefferies London Healthcare Conference
06:00am, Wednesday, 08'th Nov 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Co
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
10:33pm, Sunday, 24'th Sep 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar
BeiGene regains rights for cancer drug after Novartis deal termination
06:14am, Tuesday, 19'th Sep 2023
BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
07:00am, Thursday, 31'st Aug 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company
7 Best Cancer Stocks to Invest in Now
07:00am, Friday, 28'th Jul 2023
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which hav
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
07:00am, Friday, 07'th Jul 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company w
BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug
08:30am, Thursday, 15'th Jun 2023
BeiGene Ltd.'s ADR BGNE was down more than 7% premarket on Thursday after AbbVie's ABBV Pharmacyclics unit filed a patent-infringement lawsuit against the biotech company.
3 Top Biotech Stocks Defying the Bear Market
08:45am, Tuesday, 25'th Apr 2023
TG Therapeutics' MS drug Briumvi has had strong early sales. Viking Therapeutics reports solid clinical results from its obesity drug VK2735.
7 Biotech Stocks That Could Cure Your Portfolio Woes
07:22pm, Wednesday, 19'th Apr 2023
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
04:35am, Monday, 10'th Apr 2023
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.
Why BeiGene Stock Jumped Thursday
05:24pm, Thursday, 06'th Apr 2023
BeiGene's shares are up more than 8% this year. The company has more than 60 clinical programs.
BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024
10:03am, Wednesday, 22'nd Mar 2023
BeiGene aims to tap the area's life sciences talent pool.
Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)
11:19am, Tuesday, 28'th Feb 2023
BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks
11:17am, Monday, 27'th Feb 2023
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
